Who is sponsoring NCT03312725?

NCT03312725 is sponsored by Medical Therapy Solutions.

What drugs are being tested in NCT03312725?

Interventions in NCT03312725: WEB aneurysm embolization system.

What condition does NCT03312725 study?

NCT03312725 studies Ruptured and Unruptured Intracranial Aneurysms.

Is NCT03312725 still recruiting?

NCT03312725 is currently terminated. Last updated 10 October 2018.

Last reviewed 2018-10-10 · How we verify

NCT03312725

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mid-term Data Collection of the Treatment of Intracranial Aneurysms With the WEB™ Aneurysm Embolization System

Terminated Last updated 10 October 2018

What this trial tests

trial testing WEB aneurysm embolization system in Ruptured and Unruptured Intracranial Aneurysms in 1 participant. Terminated before completion.

Timeline

1 February 2017

Primary endpoint
26 June 2018

26 June 2018

Quick facts

Lead sponsor	Medical Therapy Solutions
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	1
Start date	1 February 2017
Primary completion	26 June 2018
Estimated completion	26 June 2018
Sites	1 location across Belgium

Drugs / interventions tested

WEB aneurysm embolization system

Conditions studied

Ruptured and Unruptured Intracranial Aneurysms — all drugs for Ruptured and Unruptured Intracranial Aneurysms →

Sponsor

Medical Therapy Solutions

Who can join

Adults 18 to 80, any sex, with Ruptured and Unruptured Intracranial Aneurysms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Flow disruption is a new endovascular approach for treatment of both ruptured and unruptured intracranial aneurysms, which involves placement of an endosaccular device (WEB) which modifies the blood flow at the level of the neck and induces intraaneurysmal thrombosis. The WEB was designed to treat wide-neck bifurcation aneurysms. This observational study will collect data about the routine practice in one center of using the WEB in ruptured and unruptured intracranial aneurysms. The primary objective is to evaluate its efficacy by assessing the anatomic outcome during follow-up.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of WEB aneurysm embolization system

Trials testing the same drug.

NCT03379714 — Mid-term Data Collection of the Treatment of Intracranial Aneurysms With the WEB™ Aneurysm Embolization System · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03312725 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical Therapy Solutions
Last refreshed: 10 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03312725.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing